INVESTMENT COMMITTEE MEMORANDUM

TO: Investment Committee Members
FROM: Sarah Chen, Principal
DATE: November 15, 2024
RE: Kappa Biotech Acquisition - $180M Growth Equity Investment

EXECUTIVE SUMMARY

Phoenix Capital Partners IV proposes a $180M growth equity investment in Kappa Biotech, a leading contract research organization (CRO) specializing in Phase II/III clinical trials for oncology therapeutics. The investment represents a 35% ownership stake at a $515M pre-money valuation (3.2x LTM revenue, 18.5x LTM EBITDA).

INVESTMENT HIGHLIGHTS

Strong Market Position
- #4 CRO in oncology clinical trials (12% market share)
- Proprietary patient recruitment network across 85 clinical sites
- 92% trial completion rate (industry average: 78%)
- Partnerships with 8 of top 10 pharma companies

Compelling Growth Drivers
- Oncology drug pipeline: 1,200+ drugs in development (CAGR: 9.8%)
- Biotech outsourcing trend: 68% of trials now outsourced (up from 52% in 2020)
- Rare disease specialization: fastest growing segment at 15% CAGR
- Geographic expansion: EU and APAC markets underpenetrated

Attractive Financial Profile
- LTM Revenue: $162M (3-year CAGR: 38%)
- LTM EBITDA: $27.8M (17.2% margin)
- Rule of 40: 55.2% (38% growth + 17.2% margin)
- 98% revenue visibility from contracted backlog
- Negative working capital due to upfront customer deposits

FINANCIAL OVERVIEW

Historical Performance ($ millions):
                    2021    2022    2023    LTM 9/30/24
Revenue            $85.2   $117.4  $148.6   $162.3
Growth %             -      37.8%   26.5%    24.2%
Gross Margin       52.3%   54.1%   56.8%    58.2%
EBITDA            $12.1   $18.7   $25.4    $27.8
EBITDA Margin     14.2%   15.9%   17.1%    17.2%
Net Income        $6.8    $10.2   $14.3    $16.5
Active Trials       24      38      52       61

Management Projections ($ millions):
                    2025E   2026E   2027E   2028E   2029E
Revenue            $205    $267    $334    $408    $485
Growth %           26.3%   30.2%   25.1%   22.2%   18.9%
EBITDA            $39.6   $56.0   $73.8   $93.8   $113.2
EBITDA Margin     19.3%   21.0%   22.1%   23.0%   23.3%
Unlevered FCF     $32.8   $46.2   $61.5   $78.9   $95.6

USE OF PROCEEDS

Total Sources: $180M
- New equity: $180M (Phoenix Capital Partners IV)

Total Uses: $180M
- Sales expansion: $65M (EU sales team, APAC JV)
- Site network expansion: $45M (25 new clinical sites)
- Technology platform: $35M (AI patient matching, EDC system upgrade)
- M&A pipeline: $25M (bolt-on site acquisitions)
- Working capital: $10M

TRANSACTION STRUCTURE

- Investment: $180M for 35% fully diluted ownership
- Security: Series A Preferred Stock
- Valuation: $515M pre-money ($695M post-money)
- Board composition: 5 seats (2 Phoenix, 2 Founders, 1 Independent)
- Liquidation preference: 1x non-participating
- Anti-dilution: Weighted average
- Drag-along rights: > 66.7% of preferred
- Protective provisions: Standard (budget, debt, M&A, equity issuance)

MANAGEMENT TEAM

Dr. Rebecca Martinez - CEO & Co-Founder
- PhD Oncology, Stanford; 18 years clinical research experience
- Previously VP Clinical Operations at Quintiles ($8B CRO)
- Founded Kappa in 2018, grown to $162M revenue
- Owns 32% equity (22.4% post-investment)

Dr. James Park - Chief Medical Officer & Co-Founder  
- MD/PhD Harvard; board certified oncologist
- Led 40+ Phase II/III trials at major pharma
- Built Kappa's scientific advisory board (12 KOLs)
- Owns 28% equity (19.6% post-investment)

Lisa Thompson - CFO (joined 2022)
- Previously CFO at $300M healthcare services PE portfolio company
- Led successful exit to strategic at 4.2x MOIC
- CPA, MBA Wharton

INVESTMENT RISKS & MITIGATIONS

Regulatory Risk
- Risk: FDA trial delays or failures impact revenue
- Mitigation: Diversified across 15+ sponsors, 60+ trials; no single trial >8% revenue

Customer Concentration  
- Risk: Top 3 customers = 42% of revenue
- Mitigation: MSAs in place (3-5 year terms); expanding customer base (32 active sponsors)

Competition Risk
- Risk: Large CROs (Labcorp, IQVIA) could compete aggressively  
- Mitigation: Differentiated oncology focus; proprietary patient network; nimble execution

Key Person Risk
- Risk: Departure of founder management team
- Mitigation: Strong equity incentives; 4-year vesting on option refresh; management continuity agreements

Execution Risk
- Risk: International expansion complexity
- Mitigation: Phased rollout; experienced country managers hired; JV model in APAC limits capital risk

RETURN ANALYSIS

Base Case (60% probability)
- Hold period: 4.5 years
- Exit multiple: 3.8x LTM revenue (20x EBITDA)
- 2029 Revenue: $485M → Exit EV: $1,843M
- Equity value @ 35%: $645M
- MOIC: 3.6x
- IRR: 38%

Upside Case (25% probability)  
- Hold period: 4.0 years
- Exit multiple: 4.5x LTM revenue (24x EBITDA)
- Accelerated growth to $520M by 2028 → Exit EV: $2,340M
- Equity value @ 35%: $819M
- MOIC: 4.5x
- IRR: 46%

Downside Case (15% probability)
- Hold period: 5.5 years
- Exit multiple: 2.8x LTM revenue (15x EBITDA)  
- Slower growth to $380M by 2029 → Exit EV: $1,064M
- Equity value @ 35%: $372M
- MOIC: 2.1x
- IRR: 16%

Expected MOIC: 3.4x | Expected IRR: 35%

EXIT STRATEGY

Primary Path: Strategic Sale (70% probability)
- Potential acquirers: Top 5 CROs looking to expand oncology capabilities
- Recent comps: 3.5-5.0x revenue, 18-25x EBITDA
- Strategic premium for patient network and site relationships

Secondary Path: Secondary Sale to Growth PE (20% probability)
- Platform for continued M&A rollup strategy
- Recent comps: 3.0-4.0x revenue, 16-22x EBITDA

Tertiary Path: IPO (10% probability)
- Public CRO comps trade at 3.2-4.8x revenue, 18-28x EBITDA
- Would need $250M+ revenue for successful public offering

DILIGENCE FINDINGS

Financial & Tax (Deloitte): Clean; no material findings
Legal (Ropes & Gray): Standard IP assignments confirmed; clinical trial contracts reviewed
Commercial (Bain & Company): TAM sizing validated; competitive positioning confirmed  
Quality of Earnings (FTI): $1.2M in non-recurring add-backs accepted; working capital normalized
IT/Cybersecurity (Deloitte): SOC 2 Type II certified; no critical findings
Insurance (Marsh): Adequate coverage; professional liability limits appropriate

RECOMMENDATION

Investment Committee approval is recommended for a $180M growth equity investment in Kappa Biotech. The opportunity offers:

✓ Compelling value creation in high-growth oncology CRO market
✓ Proven management team with deep domain expertise  
✓ Clear use of proceeds to accelerate organic + inorganic growth
✓ Strong downside protection with contracted revenue backlog
✓ Multiple exit paths with attractive strategic buyer interest

The investment aligns with Fund IV's healthcare services thesis and target return profile (3.0x+ MOIC, 30%+ IRR).

NEXT STEPS

1. IC approval vote - November 18, 2024
2. Final negotiation of SHA and investor rights - November 20-25
3. Management presentations to IC - November 22, 2024  
4. SPA execution - December 2, 2024
5. Closing - December 13, 2024 (subject to customary conditions)

Attachments:
- Financial model (Excel)
- Management presentation  
- Diligence reports summary
- Draft term sheet